WASHINGTON (AP) – The federal government has canceled a multimillion-dollar deal with Emergent Biosolutions, a Maryland-based vaccine maker with facilities in Baltimore that were found this spring to produce millions of contaminated Johnson & Johnson vaccine doses. were, the Washington Post reported.
Emergent disclosed the development on Thursday in a conference call discussing its latest financial results, the Post reported. According to the Post, Emergent said it would pay about $180 million due to the termination of the contract.
Emergent Biosolutions played a part in the Trump administration’s effort to accelerate vaccine development and distribution. But after winning a contract from the previous administration, Emergent quickly ran into production problems.
In March, materials used in the production of Oxford-AstraZeneca vaccine shots contaminated 15 million doses of Johnson & Johnson vaccine. Production was delayed by a month due to problems with the vaccines.
After that the Biden administration handed over direct control of vaccine production there to Johnson & Johnson.
In June, the Food and Drug Administration decided to discard at least 60 million additional doses of Johnson & Johnson vaccine produced at the plant.
The flaws at the Bayview factory in Baltimore hinder J&K’s efforts to become a major player in vaccinating people, especially in remote areas and poor countries. It requires only one dose and standard refrigeration and is also cheaper than some other vaccines. But there are problems with the emergency plant.
According to records obtained by the Associated Press, the FDA repeatedly cited Emergent for problems such as poorly trained staff, problems handling cracked vials and mold, and other contamination around one of its facilities.